Global Hemoglobinopathies Market Report and Forecast 2025-2034

Global Hemoglobinopathies Market Outlook

The global hemoglobinopathies market size was valued at USD 6.9 billion in 2024, driven by the rising incidence of thalassemia and sickle cell anemia across the globe. The market is expected to grow at a CAGR of 9.7% during the forecast period of 2025-2034, with the values likely to rise from USD 7.5 billion in 2025 to USD 15.9 billion by 2034.

Global Hemoglobinopathies Market Overview

Hemoglobinopathies are a group inherited blood disorders, affecting hemoglobin in the red blood cells. They are often caused by genetic mutations that lead to alteration of hemoglobin structure, function, or production. Sickle cell anemia and thalassemia are amongst the most common types of hemoglobinopathies.

It is estimated that sickle cell anemia affects approximately 100,000 United States citizens, with a higher prevalence in Black or African American race (1 in every 365 individuals ). Consequently, the hemoglobinopathies market demand is on the rise to combat the rising incidence of diseases. The market growth is driven by advancements in treatment and diagnostics. Innovations and growth in gene therapy activities is one of the major market trends. In December 2023, the United States FDA approved Exa-cel , the first CRISPR treatment for sickle cell disease. Lovo-cel, developed by Bluebird Bio is another gene therapy accepted by the FDA and will be used to treat sickle cell anemia in patients. The increasing integration of novel technologies to aid impactful treatment alternatives is expected to drive market growth in coming years.

The hemoglobinopathies market share is also poised to elevate with rising emphasis on detecting the condition early. In June 2023, Florida Atlantic University released their latest research on developing a portable tool to diagnose and monitor sickle cell anemia. Based on electrical impedance sensor, the device can analyze the rate of cell sickling and the concentration of sickled cells in the body. It can assist in quality treatment and mitigate the comorbidities associated with the disease.

Global Hemoglobinopathies Market Trends

Global Hemoglobinopathies Market Segmentation

Market Breakup by Hemoglobinopathy Type

• Sickle Cell Disease

• Thalassemia

• Other Hemoglobinopathies

The report offers an insight into types of hemoglobinopathies. It majorly constitutes sickle cell disease, and thalassemia among others.

Market Breakup by Diagnosis Type

• DNA Testing

• Hemoglobin Electrophoresis

• Complete Blood Count (CBC)

• Prenatal Testing

• Newborn Screening

• Others

Based on types of diagnostics, the report is segmented into DNA testing, hemoglobin electrophoresis, complete blood count (CBC), prenatal testing, newborn screening, and others.

Market Breakup by Treatment Type

• Blood Transfusion

• Bone Marrow Transplantation

• Gene Therapy

• Iron Chelation Therapy

• Others

The hemoglobinopathies market growth is driven by the development of advanced treatments. The report provides a detailed breakup of treatment types, which includes blood transfusion, blood marrow transplantation, gene therapy, iron chelation therapy and others. Each treatment type is deployed based on the condition and severity of the condition in patients.

Market Breakup by End User

• Hospitals

• Diagnostic Laboratories

• Research Institutions

• Blood Banks

• Others

The report offers an analysis on the basis of end users as well. Hospitals, diagnostic laboratories, research institutions, blood banks among others are amongst key end users. Each section holds significant value, owing to rising expenditures in the healthcare domain.

Market Breakup by Region

• North America

• Europe
• Asia Pacific

• Latin America

• Middle East and Africa

Geographically, the market is divided into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to dominate the hemoglobinopathies market share. The market size can be attributed to the presence of major healthcare providers in the region, undergoing significant collaborations and acquisitions to devise the best treatment solutions. With high investments to improve the healthcare and research infrastructure, Asia Pacific is poised to experience rapid market growth.

Global Hemoglobinopathies Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Novartis AG

• GlaxoSmithKline plc

• Bluebird Bio, Inc. 

• Sanofi

• F. Hoffmann-La Roche Ltd.

• Acceleron Pharma, Inc.

• Emmaus Life Sciences, Inc.

• Celon Pharma S.A.

• AstraZeneca plc

• Mast Therapeutics, Inc. (Now known as BeyondSpring)

• Pfizer Inc.

• Cipla Inc.

• Bristol Myers Squibb Company

• Juno Therapeutics (Acquired by Bristol Myers Squibb)

• Emmaus Medical, Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report

Key Queries Solved in the Hemoglobinopathies Market Report

• What is the market landscape expected to evolve in coming years?
• What is the incidence and epidemiology of hemoglobinopathies across various regions?
• Which section of the population is most susceptible to develop the condition?
• What are the key drivers and trends contributing to hemoglobinopathies market growth?
• What major constraints and challenges are affecting the market?
• What latest technologies are being used to treat hemoglobinopathies?
• Which diagnostic method is expected to lead the market share?
• What are the recent drug approvals for hemoglobinopathies treatment?
• Which companies are involved in developing most advanced treatment options for patients?
• What major collaborations and mergers are expected to transform the market during the forecast period?
• What are the major hemoglobinopathies treatment methods are being practiced in the market?